ASCO GU 2010: Effect of hypertension, nephrectomy and prior treatment on the efficacy of tivozanib (AV-951) in a phase 2 randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC)
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
